Compare Inovio Pharmaceuticals Inc (INO) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Solaredge Technologies Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Solaredge Technologies Inc trades at $49.72 (market cap $2.96B). The key difference: Solaredge Technologies Inc is far larger — about 33.2× Inovio Pharmaceuticals Inc's market cap, and Solaredge Technologies Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SEDG | |
|---|---|---|
Market Cap | $89.27M | $2.96B |
Sector | Health | Technology |
52-Week High | $2.87 | $78.51 |
52-Week Low | $1.05 | $24.42 |
Enterprise Value | $60.28M | $2.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SolarEdge Technologies (SEDG) trades at $48.65, down 9.01% in the last session, reflecting ongoing volatility. The stock shows a bearish technical signal with mixed earnings history—beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue declined to $1.18 billion in 2025, with a net loss of $405.45 million, though operating cash flow improved to $104.26 million. Analyst consensus is divided, with a hold-heavy rating and a $35.65 price target below the current price.
The outlook remains challenging due to persistent losses and competitive pressures, but potential catalysts include upcoming Q2 2026 earnings and demand for solar solutions. Key risks include high debt, margin pressures, and market sentiment shifts. Investors should weigh cost-cutting progress against sector headwinds for recovery potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
